Treatment for Neoplasm Metastasis

Phase-Based Estimates
1
Effectiveness
1
Safety
Miami Cancer Institute at Baptist Health, Inc, Miami, FL
Neoplasm Metastasis+3 More
Eligibility
18+
All Sexes
Eligible conditions
Neoplasm Metastasis

Study Summary

Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column

See full description

Eligible Conditions

  • Neoplasm Metastasis
  • Cancer, Second Primary
  • Spine Metastases
  • Neoplasms, Second Primary
  • Spine Metastasis

Treatment Effectiveness

Study Objectives

This trial is evaluating whether Treatment will improve 3 primary outcomes and 8 secondary outcomes in patients with Neoplasm Metastasis. Measurement will happen over the course of within 5 days of treatment completion.

12 months
Duration of pain response
Number of safety events
Pain response
12 months, 24 months
EuroQol (EQ-5D-5L)
Functional Assessment of Cancer Therapy-General (FACT-G)
3 months
Pain relief
baseline, 12 months
Change in response over time for the EQ-5D-5L
Change in response over time for the FACT-G
Day 5
Change in response to spine Stereotactic Body Radiotherapy (SBRT) for Brief Pain Inventory (BPI)
Change in response to spine Stereotactic Body Radiotherapy (SBRT) for EQ-5D-5L
Change in response to spine Stereotactic Body Radiotherapy (SBRT) for FACT-G

Trial Safety

Trial Design

1 Treatment Groups

Control

This trial requires 60 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months, 24 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 12 months, 24 months for reporting.

Closest Location

Miami Cancer Institute at Baptist Health, Inc - Miami, FL

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
A patient with a Zubrod performance status of 0-2 is usually considered too ill to undergo chemotherapy show original
A solid tumor from the C1 to L5 levels can cause spine metastasis show original
at the level of the conus Patients with epidural extension and a ≥ 2 mm gap between the spinal cord and the edge of the epidural lesion at the level of the conus are eligible for treatment. show original
As long as the paraspinal disease extension measures ≤ 5 cm in the greatest dimension and is contiguous with the spine metastasis, it is allowed. show original
, and the maximum time should be 12 months show original
The patient has a NRPS score of ≥ 5 at the index site(s) (as rated when the patient is not taking pain medication). show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who should consider clinical trials for neoplasm metastasis?

Add answer

Patients with neoplasm metastasis have lower QOL than patients with advanced stage disease, which is similar to other patients. Most patients would be eligible for adjuvant treatment during relapse.

Unverified Answer

What are common treatments for neoplasm metastasis?

Add answer

Overall, treatments for metastatic neoplasm (neoplasm metastasis) are not different from treatment for primary neoplasm (neoplasm tumor) in clinical characteristics. It is necessary to clarify what will affect therapeutic effect by neoplasm metastasis on the treatment outcome of systemic therapy for local and metastatic neoplasm.

Unverified Answer

What is the average age someone gets neoplasm metastasis?

Add answer

Neoplasm's metastatic rate is much higher than expected when the age was young. Most cancers occurred in individuals 25–64 years (54%). Advanced age was the primary cause of neoplasm metastasis.

Unverified Answer

What is neoplasm metastasis?

Add answer

The metastatic processes play an important role in cancer. In addition to primary cancers in patients with metastatic cancers, an increased incidence of metastases in metastatic cancers was found. A possible causal relationship between primary cancers and metastases was indicated.

Unverified Answer

How many people get neoplasm metastasis a year in the United States?

Add answer

Nearly 6 million Americans are expected to develop cancer-derived metastasis in the next 5 years, and these estimates may be over-estimated given the limitations inherent in the current American Cancer Society and United States Preventive Service Task Force estimates and the high-risk nature of cancer-derived metastasis. These numbers should be considered along with the fact that cancers thought to be at the upper end of the disease spectrum are very rare and require particular vigilance.

Unverified Answer

What causes neoplasm metastasis?

Add answer

Neoplasm metastasis can be preceded by local and system dissemination or by dissemination after surgery, particularly in the postoperative period, or by local dissemination without dissemination and in rare cases, it is only local. Different mechanisms contribute to neoplasm metastasis. Oncological surgery may compromise the elimination of neoplasm dissemination.

Unverified Answer

What are the signs of neoplasm metastasis?

Add answer

Cough, chest pain and dyspnea are the most common signs of cancer. The combination of these three can contribute to the early diagnosis of cancer.

Unverified Answer

Can neoplasm metastasis be cured?

Add answer

It is likely that, although neoplasm metastasis might be cured, it would come back or metastasize again. We advise all patients with an aggressive neoplasm disease to seek neoplasm metastasis for early diagnosis in an oncologically competent hospital.

Unverified Answer

Have there been other clinical trials involving treatment?

Add answer

The number of clinical trials for treatment had significantly increased between 2000 and 2011, suggesting a growth in treatment. A systematic review of the clinical trials concluded that the available evidence does not support the use of any particular treatment apart from conventional therapy and supportive care.

Unverified Answer

What are the chances of developing neoplasm metastasis?

Add answer

In our experience, the presence of one of the following criteria: female; a breast cancer, prostate cancer or a malignant tumor of the skin. It's crucial that the patient and the doctor are aware that at any time the patient could evolve an asymptomatic, insidious and deadly metastatic neoplasm; thus it is important to seek in its latest stages a doctor able to perform the proper imaging diagnostic tests.

Unverified Answer

What is the primary cause of neoplasm metastasis?

Add answer

The majority of primary cancer patients developed metastases. The most frequent sites of primary cancers were (in descending order of frequency): oral cavity; breast; lung; colon; thyroid; gastric; prostate; and prostate and other sites. The incidence of metastatic breast and oral cancers were similar. However, we observed that only 11% of the patients presenting a breast tumor had metastatic disease and only 0.3% had metastatic gastric cancer. Data from a recent study could be explained by an overestimation of the incidence of these metastases. Moreover, we found that only 2% of colorectal tumors were metastatic, whereas more than 20% of primary adenocarcinoma of the intestinal transit were metastatic.

Unverified Answer

What are the common side effects of treatment?

Add answer

Findings from a recent study provides a comprehensive review of the most common and rare side effects of TPMT inhibitors with DMDMs, both by patient and treatment population groups. This article is significant because it expands the patient population treated with DMDMs in clinical guidelines and provides a broad perspective on the most commonly associated toxicities of TPMT inhibitors.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Neoplasm Metastasis by sharing your contact details with the study coordinator.